Cite

HARVARD Citation

    Matthews, C. et al. (2020). Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience. Journal of oncology pharmacy practice. pp. 572-579. [Online]. 
  
Back to record